Dezima Pharma (‘Dezima’), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the inlicensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.